-
Company Insights
NewPing An Insurance (Group) Company of China – Digital Transformation Strategies
This report provides insight into Ping An's tech activities, including its digital transformation strategies, its innovation programs, its technology initiatives, its estimated ICT budget, and its major ICT contracts. Ping An Insurance (Group) Company of China (Ping An) is an integrated financial conglomerate providing insurance, banking, and investment products and services to individuals and corporate clients. The group offers a range of life and non-life insurance products such as motor insurance, property loss insurance, liability insurance, credit and trust insurance,...
-
Company Insights
NewAir France – Digital Transformation Strategies
Air France-KLM Digital Transformation Strategies Overview Air France has been focusing on using artificial intelligence, the Internet of Things (IoT), cloud-based mobile applications, big data, and drones to digitally transform its operations. The annual ICT spending of Air France was estimated at $911.8 million for 2023. A major share of this spending is earmarked for acquiring software, hardware, and ICT services from vendors. Air France-KLM is an international airline group specializing in air passenger transport, cargo transport, and aircraft maintenance....
-
Product Insights
NewMicromobility in Insurance – Market Trends and Dynamics, 2024
Micromobility in Insurance Market Report Overview Micromobility is a term used to describe the range of lightweight vehicles designed for one or two people. It largely constitutes bicycles, e-bikes, and e-scooters and is a particularly popular form of first- and last-mile transport in urban environments. City planners and policymakers are using micromobility to encourage less private vehicle usage as part of their net-zero strategies. Shared mobility services are growing in popularity across most major cities as younger consumers make use...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Camrelizumab in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Camrelizumab in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Camrelizumab in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Camrelizumab (Airuika)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pucotenlimab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pucotenlimab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pucotenlimab in Triple-Negative Breast Cancer (TNBC) Drug Details: Pucotenlimab (Puyouheng)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CRG-022 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CRG-022 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CRG-022 in Acute Lymphocytic Leukemia (ALL, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CRG-022 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CRG-022 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CRG-022 in B-Cell Acute Lymphocytic Leukemia...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CRG-022 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CRG-022 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CRG-022 in Diffuse Large B-Cell Lymphoma Drug Details: CRG-022 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CRG-022 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CRG-022 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CRG-022 in Follicular Lymphoma Drug Details: CRG-022 is under development for the...